

# HBM4EU project

science and policy  
for a healthy future

The application of extracellular vesicles  
in malignant mesothelioma diagnosis

Metka Lenassi


1<sup>st</sup> HBM4EU Training School 2018

## *Presentation outline:*


---

- Example 1: EV proteins as putative biomarkers of active HIV reservoir
- Example 2: EV miRNAs as putative biomarkers of response to treatment of malignant mesothelioma (MM)

1<sup>st</sup> HBM4EU Training School, Ljubljana, June 18-22, 2018



### Example 1: HIV infection as a chronic disease




Kulpa and Chomont; Journal of Virus Eradication 2015; 1: 59–66

1st HBM4EU Training School, Ljubljana, June 18-22, 2018



### Example 1: Aviremic individuals with non-AIDS-related disorders




Deeks et al.; Lancet. 2013 Nov 2;382(9903):1525-33.

1st HBM4EU Training School, Ljubljana, June 18-22, 2018



### Example 1: What are HIV reservoirs?



#### Conservative definition:

CD4<sup>+</sup> T-cells with silent HIV provirus, capable of replication if stimulated

#### Still relevant?

93% proviruses are defective, unable to produce infective viruses

but produce viral transcripts and proteins



active HIV reservoirs


biomarkers ?

Véronique Avettand-Fenoël et al. Clin. Microbiol. Rev. 2016;29:859-880

1st HBM4EU Training School, Ljubljana, June 18-22, 2018



### Example 1: Study aim - active HIV reservoir biomarker discovery



1st HBM4EU Training School, Ljubljana, June 18-22, 2018



### Example 1: Study subjects

#### - SCOPE cohort at UCSF: included 134 individuals

- age
- gender
- ethnicity
- blood CD4+ and CD8+ cell counts, CD4+/CD8+ ratio
- plasma HIV RNA levels
- ART regimen


#### - stratified into 4 groups:

- uninfected (n = 26): **HIV -**
- infected and ART-naïve (n = 28): **HIV+**
- aviremic infected individuals treated with ART (n = 42): **ART**
- aviremic infected elite controllers (n = 38): **EC**

1st HBM4EU Training School, Ljubljana, June 18-22, 2018



### Example 1: Nef-EVs are in plasma of half of aviremic individuals




Individual's **HIV status affects** molecular composition of plasma **EVs**.

1st HBM4EU Training School, Ljubljana, June 18-22, 2018




### Example 1: *Nef is present in plasma of half of aviremic individuals*

Plasma HIV RNA correlates  
with plasma Nef in HIV+



Plasma Nef levels depend on  
ART regimen in ART




Plasma Nef levels were **not** consistently associated with  
any of available clinical characteristics.

1st HBM4EU Training School, Ljubljana, June 18-22, 2018



### Example 2: *EVs as biomarkers of response to treatment of MM*



Genes (Basel). 2015  
Jul 8;6(3):500-11

Table 3: miRandola and miRNAExpress analysis of the most significant circulating miRNAs.


Circulating miRNAs	miR-126-3p ↓	miR-103a-3p ↓	miR-625-3p ↑	miR-29c-5p ↑	miR-92a-3p ↑
Samples	Plasma/serum	T cells/Dendritic cells	Plasma/serum	Serum/T cells	Plasma/serum/T cells/Dendritic cells
Specific carrier identified	Exosome	Ago2/Exosome	HDL (normal)/ Exosomes (prostate cancer)	Exosomes	Ago2/Exosome
Validated target and function	VCAM1 (vascular cell adhesion molecule 1)	ICOS (inducible T-cell co-stimulator), SERPINE1 (SERPINE1 mRNA Binding Protein 1), FBXW11 (F-box and WD repeat domain containing 11)	Unknown	Unknown	Unknown
Potential biomarker in other diseases	Yes: metastatic colorectal cancer*, prostate cancer*, urothelial bladder cancer*, osteoarthritis, type 2 diabetes, acute myocardial infarction, endurance exercise, stable/unstable angina	Unknown	Yes: low levels in NSCLC	Unknown	Yes: high level in gastric cancer, colorectal carcinomas, and hepatitis C infection
miRNAExpress output	Cells and circulation	Cells and circulation	Circulation	Cells	Cells and circulation

Oncotarget. 2016 Sep 6;7(36):58606-58637

1st HBM4EU Training School, Ljubljana, June 18-22, 2018



## Example 2: EVs as biomarkers of response to treatment of MM



1st HBM4EU Training School, Ljubljana, June 18-22, 2018



Univerza v Ljubljani  
Medicinska Fakulteta



Assist. Prof. Metka Lenassi

University of Ljubljana,  
Faculty of Medicine,  
Institute of Biochemistry

[metka.lenassi@mf.uni-lj.si](mailto:metka.lenassi@mf.uni-lj.si)

ORCID ID: <https://orcid.org/0000-0002-9488-6855>



This project has received funding  
from the European Union's  
Horizon 2020 research and  
innovation programme under  
grant agreement No 733032.